Literature DB >> 26867989

Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study.

Dimitrios Nasioudis1, Giovanni Sisti2, Tomi T Kanninen1, Kevin Holcomb1, Mariarosaria Di Tommaso3, Massimiliano Fambrini3, Steven S Witkin1.   

Abstract

OBJECTIVE: Squamous ovarian carcinoma (SOC) is a rare tumor. Scarcity of information about the epidemiology and prognosis of SOC hinders attempts at optimal patient management. This retrospective study of a large cohort details the clinicopathological and demographic characteristics and prognosis of women with SOC.
METHODS: A cohort of patients drawn from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database who were diagnosed with SOC between 1988 and 2012 were analyzed. Observed and disease-specific survival was estimated by Kaplan-Meier plots in women who underwent surgery as part of their cancer-related treatment. A Cox hazard regression analysis was performed to determine independent predictors of cancer-specific survival in patients with SOC.
RESULTS: We identified 341 patients with SOC with a median age at diagnosis of 55 years. Stage I, II, III and IV tumors were noted in 34%, 15%, 20.5% and 24.9% of patients, respectively. Five-year cancer-specific survival was 86% for stage I, 54.3% for stage II, 36.3% for stage III and 2.8% for stage IV disease patients. Observed and cancer-specific survival was better for patients that underwent lymphadenectomy (p=0.031). Postoperative radiotherapy was not associated with improved survival. In a multivariate analysis, independent predictors of improved cancer-specific survival were younger age, lower disease stage and lymphadenectomy.
CONCLUSIONS: SOC is typically a unilateral malignancy with a tendency toward loco-regional spread. Stage I patients have a relatively high survival rate; however, the prognosis is poor for women with abdominal or distant spread. Lymphadenectomy, but not postoperative radiotherapy, is associated with improved survival.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SEER; Squamous ovarian carcinoma; epidemiology ovarian tumor; prognosis ovarian tumor

Mesh:

Year:  2016        PMID: 26867989     DOI: 10.1016/j.ygyno.2016.02.004

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.

Authors:  Zhaoxia Wang; Li Li; Yang Wang
Journal:  Mol Med Rep       Date:  2016-04-13       Impact factor: 2.952

Review 2.  Autophagy as an emerging therapy target for ovarian carcinoma.

Authors:  Lei Zhan; Yu Zhang; Wenyan Wang; Enxue Song; Yijun Fan; Jun Li; Bing Wei
Journal:  Oncotarget       Date:  2016-12-13

Review 3.  Long non-coding RNAs in ovarian cancer.

Authors:  Lei Zhan; Jun Li; Bing Wei
Journal:  J Exp Clin Cancer Res       Date:  2018-06-19

4.  Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.

Authors:  Jinling Huang; Likun Gao; Bingshu Li; Cheng Liu; Shasha Hong; Jie Min; Li Hong
Journal:  Med Sci Monit       Date:  2019-06-08

5.  PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases.

Authors:  Caroline Eymerit-Morin; Anna Ilenko; Thomas Gaillard; Justine Varinot; Eva Compérat; Sofiane Bendifallah; Emile Darai
Journal:  Eur J Histochem       Date:  2021-03-10       Impact factor: 3.188

6.  Effects of Autophagy-Related Genes on the Prognosis and Immune Microenvironment of Ovarian Cancer.

Authors:  Jing Zhang; He Yan; Yan Fu
Journal:  Biomed Res Int       Date:  2022-07-30       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.